What question did this study set out to answer?

To investigate the differing immunological responses to CD20 depletion in relapsing multiple sclerosis (RMS) versus progressive multiple sclerosis (PPMS).

March 12, 2026Open Access

Divergent Immunological and Neurotrophic Responses to CD20 Depletion in Relapsing and Progressive Multiple Sclerosis

Key Points

To investigate the differing immunological responses to CD20 depletion in relapsing multiple sclerosis (RMS) versus progressive multiple sclerosis (PPMS).
Analyzed cytokine profiles in RMS and PPMS patients receiving ocrelizumab.
Compared immunological responses between the two MS subtypes.
Assessed treatment effects on immune modulation.
Found stronger cytokine-driven pathology in RMS than in PPMS.
Reported more significant immunomodulatory effects of ocrelizumab on cytokine profiles in RMS.
Indicated divergent immune mechanisms underpinning RMS and PPMS.

Abstract

Our findings support divergent immunological mechanisms in RMS and PPMS, with a stronger cytokine-driven pathology and more pronounced immunomodulatory effects of ocrelizumab on the cytokine profile in patients with RMS.

Perguntar à IA

Bookmark

View Full Paper